AFP and neoplasm: Not surprisingly, the implementation of a risk-stratified surveillance program for HCC is scattered with multiple barriers, which span from the histological and molecular heterogeneity of the tumor to the lack of external validation and calibration of the current biomarkers, except for alpha-fetoprotein (AFP), and the time dependence of the outcomes.